We Offer Worldwide Shipping
Login Wishlist

Duloxetine hydrochloride


  • Brand : BIOFRON

  • Catalogue Number : BN-O1196

  • Specification : 98%(HPLC)

  • CAS number : 136434-34-9

  • Formula : C18H20ClNOS

  • Molecular Weight : 333.88

  • PUBCHEM ID : 60834

  • Volume : 5mg

Available on backorder

Checkout Bulk Order?

Catalogue Number


Analysis Method





Molecular Weight




Botanical Source

Structure Type





2-thiophenepropanamine, N-methyl-γ-(1-naphthalenyloxy)-, (γS)-, hydrochloride/(S)-(+)-N-Methyl-3-(1-naphthyloxy)-3-(2-thienyl)propylamine Hydrochloride/(+)-(S)-N-methyl-g-(1-naphthyloxy)-2-thiophenepropylamine Hydrochloride/(3S)-N-methyl-3-(naphtalen-1-yloxy)-3-thiophen-2-ylpropan-1-amine chlorhydrate/(S)-Duloxetine hydrochloride/(3S)-N-Methyl-3-(1-naphthyloxy)-3-(2-thienyl)propan-1-amine hydrochloride (1:1)/(S)-N-Methyl-g-(1-naphthalenyloxy)-2-thiophenepropanamine Hydrochloride/duloxetine hcl/2-Thiophenepropanamine, N-methyl-γ-(1-naphthalenyloxy)-, (γS)-, hydrochloride (1:1)/(S)-N-Methyl-3-(naphthalen-1-yloxy)-3-(thiophen-2-yl)propan-1-amine hydrochloride/(3S)-N-methyl-3-naphthalen-1-yloxy-3-thiophen-2-ylpropan-1-amine,hydrochloride/(3S)-N-Methyl-3-(1-naphthyloxy)-3-(2-thienyl)-1-propanamine hydrochloride (1:1)/(3S)-N-methyl-3-(naphthalen-1-yloxy)-3-thiophen-2-ylpropan-1-amine hydrochloride/(3S)-N-methyl-3-(naphthalen-1-yloxy)-3-(thiophen-2-yl)propan-1-amine hydrochloride (1:1)/(3S)-N-Methyl-3-(naphthalen-1-yloxy)-3-thiophen-2-ylpropan-1-aminhydrochlorid/Duloxetine hydrochloride/Duloxetine (hydrochloride)




Flash Point


Boiling Point

466.2ºC at 760 mmHg

Melting Point



InChl Key


WGK Germany


HS Code Reference

Personal Projective Equipment

Correct Usage

For Reference Standard and R&D, Not for Human Use Directly.

Meta Tag

provides coniferyl ferulate(CAS#:136434-34-9) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of coniferyl ferulate are included as well.>> amp version: coniferyl ferulate

No Technical Documents Available For This Product.




Burning mouth syndrome (BMS) is mainly found in middle aged or elderly women and is characterized by intense burning or itching sensation of the tongue or other regions of the oral mucosa. It can be accompanied by xerostomia and dysgeusia. The syndrome generally manifests spontaneously, and the discomfort is typically of a continuous nature but increases in intensity during the evening and at night. Although BMS classically has been attributed to a range of factors, in recent years evidence has been obtained relating it peripheral (sensory C and/or trigeminal nerve fibers) or central neuropathic disturbances (involving the nigrostriatal dopaminergic system). The differential diagnosis requires the exclusion of oral mucosal lesions or blood test alterations that can produce burning mouth sensation. Patient management is based on the avoidance of causes of oral irritation and the provision of psychological support. Drug treatment for burning sensation in primary BMS of peripheral origin can consist of topical clonazepam, while central type BMS appears to improve with the use of antidepressants such as duloxetine, antiseizure drugs such as gabapentin, or amisulpride.


Burning Mouth Syndrome: A Review and Update


Francisco J Silvestre 1, Javier Silvestre-Rangil, Pia Lopez-Jornet

Publish date

2015 May 16




Introduction: Many osteoarthritis patients continue to present symptoms despite nonsurgical treatment. Duloxetine might be a viable alternative for such cases, but real clinical relevance remains unclear.

Methods: A literature review was conducted in Epistemonikos, the largest database for systematic reviews in health that compiles multiple sources, including MEDLINE, EMBASE, and Cochrane, among others. Relevant data were extracted, and information from the primary studies was reanalyzed. A subsequent meta-analysis was conducted, and summary of findings tables were constructed using the GRADE methodology.

Results and conclusions: Four systematic reviews including four randomized trials, were identified. In conclusion, while duloxetine slightly improves pain and functionality in osteoarthritis patients, its use is associated with frequent adverse side effects. Therefore, the benefit/risk balance appears unfavorable.


Is Duloxetine an Alternative in the Treatment of Osteoarthritis?


Joaquin Ananias 1, Sebastian Irarrazaval 2

Publish date

2017 Oct 18




Chemotherapy-induced peripheral neuropathy (CIPN) is one of the most disabling and demoralizing problems that arise for cancer survivors. When investigating symptoms of numbness, tingling, or pain in the extremities, it is critical to determine whether the problem is neuropathic, somatic, or mixed. If the diagnosis is CIPN, it is important to weigh the potential benefits and harms of possible treatment options, and to devise an evidence-based multimodality treatment program. Such programs may include mixtures of opioid and nonopioid adjunctive medications, based on evidence from CIPN trials, and also extrapolation from trials in patients with other neuropathic pain syndromes-although such extrapolating must be done with caution, since other syndromes sometimes respond to agents that CIPN does not respond to. Other components of a successful program might include exercise; and possibly neuromodulation via acupuncture, spinal cord electrical stimulation, or neurocutaneous stimulation. There is good randomized trial evidence that most of the anticonvulsants and tricyclic antidepressants typically prescribed for neuropathic pain have little or no effect on CIPN, but there is some evidence of efficacy for duloxetine-however, clinical practice with regard to pharmacologic treatment of CIPN often does not reflect these data. We review here the recommendations of the American Society of Clinical Oncology, as well as some new and promising approaches to neuropathy, including new neuromodulation techniques.


New Practical Approaches to Chemotherapy-Induced Neuropathic Pain: Prevention, Assessment, and Treatment


Neil Majithia, Charles L Loprinzi, Thomas J Smith

Publish date

2016 Nov 15

Description :

Empty ...